Impact of Trans-catheter Aortic Valve Implantation on Renal Function

Inclusion Criteria: * Age \>18 years with a life expectancy \>1 year; * Patient candidate for percutaneous aortic valve implantation after formal indication of our "Heart Team". * Patient performed at least one contrast-based exam other than the TAVI procedure in the previous two months. * Patients had adequate renal function assessment after each contrast medium administration (TAVI procedure included) with at least three post-procedural measurements in the following 5 days. * Patients were informed of the possibility to be the object of anonymized data collection for study protocols approved by the internal Ethical Committee and had provided written informed consent to the procedure (for patients before 2018) or had provided written informed consent to the research purposes of IRCCS (for patients from 2018 to date). Exclusion Criteria: * Female with childbearing potential or lactating; * Acute or chronic end-stage renal dysfunction defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m2); * Candidate for dialysis treatment; * Co-morbidities that could interfere with the completion of study procedures, or life expectancy of less than 1 year; * Absent or incomplete renal function assessment after each contrast-based procedure; * Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study;